FORE Biotherapeutics to Present Plixorafenib Data at Oncology Meetings
The company plans to present new clinical and preclinical data on plixorafenib at upcoming oncology medical meetings. The body says the SNO 2026 presentation will include updated long-term efficacy and safety data from a Phase 1/2a study.